These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34214736)

  • 1. Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Allograft Recipients.
    Tamari R; Brown S; Devlin SM; Kosuri S; Maloy MA; Ponce DM; Sauter C; Shaffer B; Dahi P; Young JW; Jakubowski A; Papadopoulos EB; Castro-Malaspina H; Perales MA; Giralt SA; Gyurkocza B
    Transplant Cell Ther; 2021 Oct; 27(10):852.e1-852.e9. PubMed ID: 34214736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts.
    Jacob RP; Flynn J; Devlin SM; Maloy M; Giralt SA; Maslak P; O'Reilly RJ; Tonon JA; Perales MA; Avecilla ST; Cho C
    Transplant Cell Ther; 2021 Aug; 27(8):697.e1-697.e5. PubMed ID: 33991721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes with allogeneic stem cell transplant using cryopreserved versus fresh hematopoietic progenitor cell products.
    Wan BA; Lindo L; Mourad YA; Chung S; Forrest D; Kuchenbauer F; Nantel S; Narayanan S; Nevill T; Power M; Rodrigo J; Sanford D; Song K; Stubbins RJ; Sutherland H; Toze CL; White J; Roy C; Hay KA
    Cytotherapy; 2024 Oct; 26(10):1210-1216. PubMed ID: 38819367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
    Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Reconstitution Following TCRαβ/CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients.
    Arnold DE; MacMath D; Seif AE; Heimall JR; Wang Y; Monos D; Grupp SA; Bunin NJ
    Transplant Cell Ther; 2021 Feb; 27(2):169.e1-169.e9. PubMed ID: 33830028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
    Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G
    Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34
    Scordo M; Bhatt V; Hilden P; Smith M; Thoren K; Cho C; Shah GL; Maloy MA; Papadopoulos EB; Jakubowski AA; Avecilla ST; O'Reilly RJ; Castro-Malaspina H; Tamari R; Shaffer BC; Boelens JJ; Perales MA; Giralt SA
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1526-1535. PubMed ID: 30831208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.
    Rezvani AR; Storer BE; Guthrie KA; Schoch HG; Maloney DG; Sandmaier BM; Storb R
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):105-12. PubMed ID: 25278458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.
    Kanate AS; Craig M; Cumpston A; Saad A; Hobbs G; Leadmon S; Bunner P; Watkins K; Bulian D; Gibson L; Abraham J; Remick SC; Hamadani M
    Hematol Oncol Stem Cell Ther; 2011; 4(4):149-56. PubMed ID: 22198185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotherapy-Free Regimen Improves Non-Relapse Mortality and Immune Recovery Among the Recipients of αβ TCell-Depleted Haploidentical Grafts: Retrospective Study in Childhood Leukemia.
    Shelikhova L; Glushkova S; Nikolaev R; Dunaikina M; Zhekhovtsova Z; Blagov S; Khismatullina R; Balashov D; Kurnikova E; Pershin D; Muzalevskii Y; Kazachenok A; Osipova E; Trakhtman P; Maschan A; Maschan M
    Transplant Cell Ther; 2021 Apr; 27(4):330.e1-330.e9. PubMed ID: 33836878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation.
    Lakkaraja M; Scordo M; Mauguen A; Cho C; Devlin S; Ruiz JD; Klein E; Avecilla ST; Boulad F; Cancio MI; Curran KJ; Jakubowski AA; Kernan NA; Kung AL; O'Reilly RJ; Papadopoulos EB; Prockop S; van Roessel I; Scaradavou A; Shaffer BC; Shah G; Spitzer B; Tamari R; Giralt SA; Perales MA; Boelens JJ
    Blood Adv; 2022 Feb; 6(3):1054-1063. PubMed ID: 34788361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryopreservation of Allogeneic Hematopoietic Cell Products During COVID-19 Pandemic: Graft Characterization and Engraftment Outcomes.
    Keyzner A; Azzi J; Jakubowski R; Sinitsyn Y; Tindle S; Shpontak S; Kwon D; Isola L; Iancu-Rubin C
    Transplant Proc; 2023 Oct; 55(8):1799-1809. PubMed ID: 37210273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies].
    Hu SS; Wu YB; Zhu PP; Shi JM; Yu J; Zhao YM; Lai XY; Liu LZ; Fu HR; Huang H; Luo Y
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):992-1002. PubMed ID: 36709104
    [No Abstract]   [Full Text] [Related]  

  • 17. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.
    Konuma T; Kanda J; Yamasaki S; Harada K; Shimomura Y; Terakura S; Mizuno S; Uchida N; Tanaka M; Doki N; Ozawa Y; Nakamae H; Sawa M; Matsuoka KI; Morishige S; Maruyama Y; Ikegame K; Kimura T; Kanda Y; Ichinohe T; Atsuta Y; Yanada M
    Transplant Cell Ther; 2021 Apr; 27(4):334.e1-334.e11. PubMed ID: 33836881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.
    Körbling M; Huh YO; Durett A; Mirza N; Miller P; Engel H; Anderlini P; van Besien K; Andreeff M; Przepiorka D; Deisseroth AB; Champlin RE
    Blood; 1995 Oct; 86(7):2842-8. PubMed ID: 7545476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot Study of Donor-Engrafted Clonal Hematopoiesis Evolution and Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation Recipients Using a National Registry.
    Gillis N; Padron E; Wang T; Chen K; DeVos JD; Spellman SR; Lee SJ; Kitko CL; MacMillan ML; West J; Tang YH; Teng M; McNulty S; Druley TE; Pidala JA; Lazaryan A
    Transplant Cell Ther; 2023 Oct; 29(10):640.e1-640.e8. PubMed ID: 37517612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.